Acadia’s Persistence With Pimavanserin In Parkinson’s Psychosis Pays Off

After meeting with FDA, Acadia announces it needs only one pivotal study for pimavanserin. The company has canceled a second study and expects to file at the end of 2014. Faster NDA pathway could mean launch a year earlier than expected.